Feedback Share Discussion Threads

[davydoo] 06/7/2015 14:29

lol good spot LR2

[lr2] 06/7/2015 14:16

PR company taking shares instead of cash for work done.

[lr2] 03/7/2015 17:33

Talk with Dr. Balaji Ganeshan regarding TexRAD starts at 20:30 and lasts approx. 15 minutes.

[lr2] 30/6/2015 17:56

Feedback PLC – Dr Balaji Ganeshan talking at UK Radiological Congress 2015



Dr. Balaji Ganeshan, Chief Scientist & New Business Officer at Feedback PLC, (and group companies TexRAD and CCI Ltd) will be giving a talk entitled “Quantifying Tumour heterogeneity with TexRAD texture analysis on CT and MRI”

Where: at the Guerbet Laboratories Ltd stand at UK Radiological Congress 2015 in Liverpool, UK (30th June 4pm and 1st July 11am).

Full details of the conference can be found on the UKRC website here.

Attendees and delegates please register at the Guerbet stand.

Guerbet Group website.



And a couple of Guerbet videos.

[lr2] 30/6/2015 12:53

Endourology presentation 2:30 - 3:30 this afternoon. Might have something to do with the price rise.

[blueball] 30/6/2015 12:49

3p finish today by the look.

[blueball] 25/6/2015 15:13

Cant believe all the sells.

[lr2] 24/6/2015 17:08

So they should. There's only 3 more trading days before the presentation.

[blueball] 24/6/2015 16:51

Buyers return.

[blueball] 19/6/2015 20:18

Bullish coverage.

[lr2] 17/6/2015 16:15

Remember this?

Mr Ben Turney, a leading authority on stone disease in the UK, commented:

"Shock Wave Lithotripsy (SWL) is a well-established non-invasive surgical procedure for urolithiasis. However around 30-40% of patients do not achieve stone clearance and proceed to alternative treatments. We have demonstrated in this first preliminary study that TexRAD CT textural analysis appears to be an independent novel predictive biomarker for SWL success. TexRAD CT texture analysis may be a useful tool for risk-stratification and more accurately triaging those patients who will benefit from SWL. The next step is to undertake a prospective study to ascertain the clinical utility of this finding in a large population. Additionally, we shall explore other research questions such as assessing the stone composition and differentiate between actual stones and those conditions that mimic stone-like characteristics to increase diagnostic confidence and prevent unnecessary costly investigation and treatments."

Dr. Balaji Ganeshan, Chief Scientist & New Business Officer of the Company's subsidiaries TexRAD Ltd & Cambridge Computed Imaging Ltd commented:

"We are delighted with the positive results from the preliminary study within a few weeks of signing the research agreement with Mr Ben Turney and the team at Oxford. This is very encouraging news and provides an opportunity for Feedback Plc to develop a TexRAD based kidney stone software product dedicated to the management of kidney stone patients."

Mr Ben Turney and team have further submitted their preliminary results as an abstract for a possible presentation to the Challenges in Endourology meeting (hxxp://www.challenges-endourology.com) in Paris in June 2015.



Well, a presentation is definitely taking place. Tuesday June 30th 14:30 - 15:30.

[blueball] 16/6/2015 18:44

Good news could be about due..I'll go with that.

[sja123] 16/6/2015 14:57

:-)....True..It does sound a bit amateur with no real feel for what the company does etc...but might catch the attention of a few...

[lr2] 16/6/2015 14:45

Reads like it was cobbled together during playtime by a ten year old so I looked the author up. Was amazed to see he's an OAP. Daft old codger. Still he knows an interesting company when he sees one.

[sja123] 16/6/2015 14:35

Hello Share Sappers. I beg your indulgence to return to Feedback (FDBK), the company which uses whizzo computers to help diagnose and monitor many types of cancer. As reported previously, this could be a topping investment. Though, as per usual, we should always add a cautionary note about medical pioneers.This is because they can always be taken over by some even more revolutionary gizmo or they might not get every licence they hope for.There is also the worry that the NHS, to name just one medical services giant, is short of money these days as the number of patients grow, fuelled by longevity.Having said that, I want to go over a few reasons why I'm so enthusiastic about Feedback.One, it is a small company, capitalised at just £5million and has a comparatively small number of shares out there.A heck of a lot of these shares are owned by directors, families and friends.This means there are even fewer shares in the market place. And we all know the effects of limited supply and demand.Also the very fact that the big cheeses of Feedback have so much skin in the game is very re-assuring.As usual with this sort of pioneering company, a bit of good news - like a tasty new contract - will send the shares skywards. And, after a fallow time, good news could be about due.The shares reached a high not so long ago at 3.2 pence. It's softened to 2.8p since then, as profit takers have succumbed to temptation. But nothing has happened to justify the slight fall, and if you read the company's bumph and believe it, there should be some jolly profit to come.I've see nothing I've read to knock my faith in this lot and so I will hold my not inconsiderable holding (for a penny share). With the exception, perhaps of frequently high spreads, and the inability to, so far, make a profits .

[blueball] 12/6/2015 22:23

hxxp://www.barchart.com/quotes/stocks/FDBK.LS

[sja123] 12/6/2015 18:12

I wouldn't argue with that blueball.... Will be holding here for some time personally, as the story unfolds.....

[blueball] 12/6/2015 16:49

Looking good here sja I have my own idea of where this is going at least 5p imo.

[sja123] 12/6/2015 16:39

Chart looks set up for a breakout perhaps....next week?...